Jeffrey A. Cohen

Education

Notable contributions

• Global Principal Investigator of the ACT clinical trial
• Global Principal Investigator of the TRANSFORMS Phase III trial of Fingolimod, a novel oral agent for use in treating Multiple Sclerosis, the primary results of which were presented at the American Academy of Neurology Annual Meeting in May 2009.
• Global Principal Investigator of the IMPACT trial, the first study to use the MS Functional Composite as the primary outcome measure in a clinical trial.
• Co-Editor of the textbook ,
• Fellowship Director of the Mellen Center for MS National Multiple Sclerosis Society-supported Fellowship